NCT00868062

Brief Summary

In situations such as dehydration, illness and surgery, fluid 'drips' are given to patients to keep them hydrated. Different fluids stay in the circulation for different lengths of time. For example, some types of fluid remain in the circulation for a short time which means patients would need to be given more fluid to achieve the desired effects. Giving a lot of fluid to sick patients can in itself cause problems, for example, it can affect the way the bowels work and delay the patient's recovery from illness. In these situations the investigators use specialized fluids called colloids, that are designed to stay in the circulation for longer. This means a smaller amount of fluid needs to be used and less problems are likely to occur. There are two different types of colloids that are commonly used, but the investigators do not know which of them is better. The purpose of this study is to investigate which of the two different colloids (one is called Gelofusin and the other is called Voluven) works better in patients who undergo surgery. Knowing which of the two fluids works best in patients will help us improve the care of surgical patients. The investigators hypothesis is that the fluid that has the larger size of molecules as part of the solution will work better during surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Apr 2009

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 24, 2009

Completed
8 days until next milestone

Study Start

First participant enrolled

April 1, 2009

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2011

Completed
Last Updated

November 16, 2011

Status Verified

November 1, 2011

Enrollment Period

2.6 years

First QC Date

March 23, 2009

Last Update Submit

November 15, 2011

Conditions

Keywords

The responses of patients to 1L infusions of Gelofusine (succinylated gelatine 40g/L) and Voluven (6% hydroxyethyl starch in 0.9% saline) intraoperatively.

Outcome Measures

Primary Outcomes (1)

  • The magnitude and duration of the plasma volume expanding effects of the two colloids.

    4 hours

Secondary Outcomes (1)

  • To determine the effects of the two infusions on serum and urinary osmolality, sodium, potassium, chloride, bicarbonate, urea, albumin, microalbumin and haematological parameters.

    4 hours

Study Arms (1)

1

EXPERIMENTAL
Other: Succinylated gelatine, 40g/L, (Gelofusine - B Braun)

Interventions

1 litre infusion following induction of anaesthesia

1

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male and female patients aged 18-60 years undergoing elective laparoscopic cholecystectomy for proven gallstone disease.
  • BMI of 20-26 kg/m2
  • Able to give voluntary written informed consent to participate in the study
  • Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures
  • (Females of child bearing age will be offered a pregnancy test)

You may not qualify if:

  • Patients with a known history of allergic reaction to the colloid infusions
  • Patients with acute cholecystitis or the systemic inflammatory response syndrome
  • Patients with a serum bilirubin \> 25 μmol/l
  • Females who are pregnant or refuse to have a pregnancy test
  • Patients with a haemoglobin \< 10 g/l
  • Patients with a history of acute pancreatitis
  • Patients likely to undergo common bile duct exploration
  • Patients with renal impairment, ischaemic heart disease, cardiac failure and chronic restrictive airways disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sherwood Forest Hospitals NHS Foundation Trust

Mansfield, Nottinghamshire, NG17 4JL, United Kingdom

Location

Study Officials

  • Dileep Lobo, FRCS

    University of Nottingham

    PRINCIPAL INVESTIGATOR
  • Mukul Dube, FRCS

    Sherwood Forrest Hospitals NHS Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 23, 2009

First Posted

March 24, 2009

Study Start

April 1, 2009

Primary Completion

November 1, 2011

Study Completion

November 1, 2011

Last Updated

November 16, 2011

Record last verified: 2011-11

Locations